Search
Emergent BioSolutions Inc
EBSAdd to Watchlist
4.590USD
+0.105+2.34%
Close 08-14 16:00（ET）Quotes delayed by 15 min
235.47MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Emergent BioSolutions Inc is 8.00, ranking 59 out of 156 in the Pharmaceuticals industry. The average price target is 13.50, with a high of 15.00 and a low of 12.00.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
11.000
Target Price
+144.99%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
Emergent BioSolutions Inc
EBS
2
Biogen Inc
BIIB
37
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
32
Regeneron Pharmaceuticals Inc
REGN
30
1
2
3
...
32
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Emergent BioSolutions Inc's expected revenue for the next quarter?
Emergent BioSolutions Inc's expected revenue is 125.80M.
What is Emergent BioSolutions Inc's price target?
Analysts forecast that Emergent BioSolutions Inc's price target is USD 13.50, with the highest forecast at USD 15.00 and the lowest forecast at USD 12.00.
How have Emergent BioSolutions IncEBS's recent earnings per share performed?
The market expectation was USD -3.49, while Emergent BioSolutions IncEBS's earnings per share (EPS) for the previous quarter was USD 0.13. EPS for the next quarter is expected at USD -0.41.
What is the analyst rating for Emergent BioSolutions Inc?
Based on the ratings of Emergent BioSolutions Inc's stock from 2 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.